Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines

Antimicrobial Agents and Chemotherapy
A BekkerA C Hesseling

Abstract

There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during infancy (<12 months of age), when drug disposition may differ. Intensive pharmacokinetic sampling was performed in infants routinely receiving antituberculosis treatment, including rifampin, isoniazid, pyrazinamide, and ethambutol, using World Health Organization-recommended doses. Regulatory-approved single-drug formulations, including two rifampin suspensions, were used on the sampling day. Assays were conducted using liquid chromatography-mass spectrometry; pharmacokinetic parameters were generated using noncompartmental analysis. Thirty-nine infants were studied; 14 (36%) had culture-confirmed tuberculosis. Fifteen (38%) were premature (<37 weeks gestation); 5 (13%) were HIV infected. The mean corrected age and weight were 6.6 months and 6.45 kg, respectively. The mean maximum plasma concentrations (Cmax) for rifampin, isoniazid, pyrazinamide, and ethambutol were 2.9, 7.9, 41.9, and 1.3 μg/ml, respectively (current recommended adult target concentrations: 8 to 24, 3 to 6, 20 to 50, and 2 to 6 μg/ml, respectively), and the mean areas under the concentration-time curves from 0 to 8 h (AUC0-8) were 12.1, 24.7, 239.4, and 5.1 μg · h/m...Continue Reading

References

Jan 1, 1986·Therapeutic Drug Monitoring·J R KoupA L Smith
Apr 1, 1993·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·R C Sahoo
Sep 19, 2003·The New England Journal of Medicine·Gregory L KearnsRalph E Kauffman
May 8, 2004·International Journal of Pharmaceutics·Ramesh Panchagnula, Shrutidevi Agrawal
May 24, 2005·Archives of Disease in Childhood·H S SchaafP R Donald
Oct 20, 2006·Clinical Pharmacokinetics·Imke H BartelinkJohn N van den Anker
Jun 21, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Amita GuptaUNKNOWN Byramjee Jeejeebhoy Medical College-Johns Hopkins University Study Group
Dec 1, 2007·BMC Infectious Diseases·H Simon SchaafPeter R Donald
Apr 28, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Helen McIlleronPeter R Donald
May 13, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sekai ChideyaJordan W Tappero
Sep 15, 2009·Clinical and Experimental Dermatology·K L HonT F Leung
Jan 20, 2010·Clinical Rheumatology·Nuray Aktay AyazSeza Ozen
Mar 15, 2011·Archives of Disease in Childhood. Fetal and Neonatal Edition·Tim J ColeUNKNOWN RCPCH Growth Chart Expert Group
May 17, 2013·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·G RamachandranS Swaminathan
Feb 5, 2014·Antimicrobial Agents and Chemotherapy·A BekkerA C Hesseling
Feb 6, 2015·American Journal of Respiratory and Critical Care Medicine·Martin J BoereeUNKNOWN PanACEA Consortium
Mar 12, 2015·The Journal of Antimicrobial Chemotherapy·R MlothaS Ward
Apr 19, 2015·BMC Infectious Diseases·Aparna MukherjeeRakesh Lodha
Sep 26, 2015·Journal of the Pediatric Infectious Diseases Society·Awewura KwaraSampson Antwi

❮ Previous
Next ❯

Citations

Mar 28, 2017·Expert Opinion on Pharmacotherapy·Helena RabieH Simon Schaaf
Mar 24, 2017·The Journal of Antimicrobial Chemotherapy·Devan JaganathPeter R Donald
Mar 6, 2018·Basic & Clinical Pharmacology & Toxicology·Falko PartoschUrsula Gundert-Remy
Nov 6, 2018·Journal of the Pediatric Infectious Diseases Society·Museveni JustineTania A Thomas
Dec 7, 2018·Expert Review of Anti-infective Therapy·Helen McIlleron, Maxwell T Chirehwa
Mar 1, 2019·Indian Journal of Pediatrics·Andrea T Cruz, Jeffrey R Starke
Aug 14, 2020·The Journal of Antimicrobial Chemotherapy·Tom G JacobsUNKNOWN WHO Paediatric Antiretroviral Working Group
May 7, 2019·Journal of Chemotherapy·Tommaso MatucciElena Chiappini
Oct 6, 2017·Acta Crystallographica Section B, Structural Science, Crystal Engineering and Materials·Kashyap Kumar SarmahRanjit Thakuria
Nov 9, 2018·Clinical Pharmacokinetics·Alper DaskapanJan-Willem C Alffenaar
Sep 17, 2021·The Journal of Antimicrobial Chemotherapy·Anthony J Garcia-PratsAnneke C Hesseling
May 30, 2021·The European Respiratory Journal·Antoni Noguera-JulianNicole Ritz
Dec 7, 2018·Science Translational Medicine·Elizabeth W TuckerSanjay K Jain
Aug 23, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Chishala ChabalaHelen McIlleron

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.